参考文献/References:
[1] CARDONA A F,ORD EZ-REYES C,RUIZ-PA-TIO A,et al.EGFR inhibitors plus bevacizumab are superior than EGFR inhibitors alone as first-line setting in advanced NSCLC with EGFR mutations and BIM deletion polymorphisms （BIM-CLICaP）[J].JCO Precis Oncol,2021,5：839-848.
[2] SANTONI-RUGIU E,MELCHIOR L C,URBANS-KA E M,et al.Intrinsic resistance to EGFR-tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer：differences and similarities with acquired resistance[J].Cancer（Basel）,2019,11（7）：923.
[3] VYSE S,HUANG P H.Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer[J].Signal Transduct Target Ther,2019,4：5.
[4] JIA K Y,YANG S,CHEN B,et al.Advanced lung adenocarcinoma patient with EGFR exon 20 insertion benefits from high-dose furmonertinib for nine months after progression from mobocertinib：a case report[J].Ann Transl Med,2022,10（6）：386.
[5] BURNETT H,EMICH H,CARROLL C,et al.Epidemiological and clinical burden of EGFR exon 20 insertion in advanced non-small cell lung cancer：A systematic literature review[J].PLoS One,2021,16（3）：e0247620.
[6] OXNARD G R,LO P C,NISHINO M,et al.Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions[J].J Thorac Oncol,2013,8（2）：179-184.
[7] YANG J C,SEQUIST L V,GEATER S L,et al.Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations：a combined post-hoc analysis of LUX-Lung 2,LUX-Lung 3,and LUX-Lung 6[J].Lancet Oncol,2015,16（7）：830-838.
[8] NAIDOO J,SIMA C S,RODRIGUEZ K,et al.Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas：clinical outcomes and response to erlotinib[J].Cancer,2015,121（18）：3212-3220.
[9] FDA grants accelerated approval to mobocertinib for metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations[EB/OL].（2021-09-16）[2021-11-02].https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-mobocertinib-metastatic-non-small-cell-lung-cancer-egfr-exon-20.
[10] CASTA N E,MARTíN P,ROLFO C,et al.Epidermal Growth Factor Receptor targeting in non-small cell lung cancer：revisiting different strategies against the same target[J].Curr Drug Targets,2014,15（14）：1273-1283.
[11] FDA.EXKIVITYTM（mobocertinib）capsules,for oral use initial U.S[EB/OL].（2021-09-16）[2021-11-05].https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215310s000lbl.pdf.
[12] GONZALVEZ F,VINCENT S,BAKER T E,et al.Mobocertinib （TAK-788）：a targeted inhibitor of EGFR exon 20 insertion mutants in non-small cell lung cancer[J].Cancer Discov,2021,11（7）：1672-1687.
[13] ZHANG S,JIN S,GRIFFIN C,et al.Effects of itraconazole and rifampin on the pharmacokinetics of mobocertinib(tak-788),an oral epidermal growth factor receptor inhibitor,in healthy volunteers[J].Clin Pharmacol Drug Dev,2021,10（9）：1044-1053.
[14] NIH.A Study of TAK-788 in adults with non-small cell lung cancer [EB/OL].（2016-03-23）[2021-11-05].https://clinicaltrials.gov/study/NCT02716116?term=NCT02716116&rank=1）.
[15] ZHOU C,RAMALINGAM S S,KIM T M,et al.Treatment outcomes and safety of mobocertinib in platinum-pretreated patients with EGFR exon 20 insertion-positive metastatic non-small cell lung cancer a phase1/2 open-label nonrandomized clinical trial[J].JAMA Oncol,2021,7（12）：e214761.
[16] RIELY G J,NEAL J W,CAMIDGE D R,et al.Activity and safety of mobocertinib(TAK-788) in previously treated non-small cell lung cancer with egfr exon 20 insertion mutations from a phase Ⅰ/Ⅱ trial[J].Cancer Discov,2021,11（7）：1688-1699.
[17] HIDA T,NISHINO M,YOH K,et al.A phase I dose-escalation study of mobocertinib（TAK-788）,an oral tyrosine kinase inhibitor（TKI）,in Japanese NSCLC patients[abstract no.1246P][J].Annals of Onco-logy,2021,32 （suppl_5）：S949-S1039.
[18] OU S H I,Lin H M,Hong J L,et al.Comparative effectiveness of mobocertinib and standard of care in patients with NSCLC with EGFR exon 20 insertion mutations: An indirect comparison[J].2023,179:107186.